This article explores a groundbreaking phase 2 clinical trial investigating the safety and efficacy of dual thrombolytic therapy with mutant prourokinase and small bolus alteplase in the treatment of ischemic stroke. The study provides invaluable insights into potential stroke treatment strategies and paves the way for further research in optimizing stroke management and patient outcomes.
